Date: 2015-09-29
Type of information: Licensing agreement
Compound:
Company: The Lead Discovery Center (LDC) (Germany) Infinity Pharmaceuticals (USA - MA)
Therapeutic area: Cancer - Oncology
Type agreement: development licensing
Action mechanism:
Disease:
Details: * On September 29, 2015, The Lead Discovery Center and Infinity Pharmaceuticals will work together to jointly select high-potential cancer drug discovery projects from the LDC’s portfolio and its broad academic network. In the context of their collaboration, the LDC will give Infinity insight into project opportunities arising from its diverse portfolio and its extensive academic network. This includes leading universities as well as renowned institutes from Germany’s world-class research organizations, the Max Planck Society and the Helmholtz Association. The focus will be on the field of oncology. Infinity will review proposals with the goal of identifying one or more programs for either licensing or collaboration. For the projects selected, Infinity may draw on the LDC’s expertise and resources in early drug discovery and development. The partners will agree on the scope and terms of potential co-development partnerships on a project-by-project basis to ensure optimal project progress and a fair distribution of investments and potential returns. Any revenue the LDC may receive from commercialization will be shared with the academic inventors and collaborating institutions.
Financial terms:
Latest news:
